期刊
ANNALS OF HEPATOLOGY
卷 18, 期 2, 页码 291-297出版社
ELSEVIER ESPANA
DOI: 10.1016/j.aohep.2019.04.003
关键词
-
资金
- EU FP7 Project Cancer Vaccine development for Hepatocellular Carcinoma - HEPAVAC [602893]
- Italian Ministry of Health through Institutional Ricerca Corrente
- Transcan2 - HEPAMUT project
- HEPAVAC
- Ricerca Corrente
Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflamed livers due to underlying chronic liver disease caused by viral and non-viral pathogenesis. This inflammation leads to tumor development and is associated to higher tumor immunogenicity. For this reason immunotherapeutic approaches may be suitable therapeutic strategies for HCC. Indeed, several preclinical and clinical data support this hypothesis showing that immunotherapy and even more their combination may be a good alternative candidate for the treatment of HCC patients. However, considering that the liver plays a central role in host defense as well as in the maintenance of self-tolerance, it is characterized by a strong intrinsic immune suppressive microenvironment as well as by a high immune evasion, which may represent a major impediment for an effective immune response against tumor. Furthermore, the low expression of tumor antigens on liver cancer cells leads to a lower T-cell activation and tumor infiltration, resulting in a less efficient control of the tumor growth and, consequently, in a worse clinical outcome. For this reason, strategies should be developed to counteract the different factors in the HCC tumor microenvironment playing a major role in reducing the effects of immunotherapy. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Fundacion Clinica Medica Sur, A.C.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据